PMID- 30483954
OWN - NLM
STAT- MEDLINE
DCOM- 20190219
LR  - 20200225
IS  - 1432-2307 (Electronic)
IS  - 0945-6317 (Linking)
VI  - 474
IP  - 2
DP  - 2019 Feb
TI  - Analysis of the prognostic relevance of sex-steroid hormonal receptor mRNA 
      expression in muscle-invasive urothelial carcinoma of the urinary bladder.
PG  - 209-217
LID - 10.1007/s00428-018-2496-9 [doi]
AB  - Muscle-invasive urothelial carcinoma of the urinary bladder (UCB) often recurs 
      following radical cystectomy (RC). An altered expression of sex-steroid hormone 
      receptors has been associated with oncological outcomes of UCB and may represent 
      therapeutic targets. Here the expression of different hormone receptors was 
      measured on mRNA levels in patients treated by RC and associated with outcomes. 
      Androgen receptor (AR), estrogen receptor 1 (ESR1), and progesterone receptor 
      (PGR) mRNA expression was assessed by quantitative reverse transcription 
      polymerase chain reaction (RT-qPCR) in RC samples of 87 patients with a median 
      age of 66 (39-88) years. Univariate and multivariate analyses were performed to 
      test associations with pathological and clinical characteristics as well as 
      recurrence-free (RFS) and disease-specific survival (DSS). AR mRNA expression was 
      lower in comparison with ESR1 and PGR expression (p < 0.0001). In univariate 
      analysis, high expression levels of AR were associated with reduced RFS (HR 2.8, 
      p = 0.015) and DSS (HR 2.8, p = 0.010). High AR mRNA expression and a positive 
      lymph node status were independent predictors for reduced RFS (HR 2.5, 
      p = 0.0049) and DSS (HR 3.4, p = 0.009). In patients with low AR mRNA expression, 
      an increased ESR1 and PGR mRNA expression were associated with reduced RFS and 
      DSS. High expression levels of AR are significantly associated with adverse 
      outcome in patients with muscle-invasive UCB following RC. ESR1 and PGR 
      expression status can further stratify patients with low AR expression into 
      subgroups with significantly reduced RFS and DSS. Therapeutic targeting of AR may 
      influence outcomes in patients with UCB.
FAU - Erben, Philipp
AU  - Erben P
AD  - Department of Urology, University Medical Centre Mannheim, Medical Faculty 
      Mannheim, University of Heidelberg, Mannheim, Germany.
FAU - Sikic, Danijel
AU  - Sikic D
AD  - Department of Urology and Pediatric Urology, Friedrich-Alexander University (FAU) 
      Erlangen-Nurnberg, Erlangen, Germany. danijel.sikic@uk-erlangen.de.
FAU - Wirtz, Ralph M
AU  - Wirtz RM
AD  - Stratifyer Molecular Pathology GmbH, Cologne, Germany.
FAU - Martini, Thomas
AU  - Martini T
AD  - Department of Urology and Pediatric Urology, University of Ulm, Ulm, Germany.
FAU - Weis, Cleo-Aron
AU  - Weis CA
AD  - Institute of Pathology, University Medical Centre Mannheim, Medical Faculty 
      Mannheim, University of Heidelberg, Mannheim, Germany.
FAU - Breyer, Johannes
AU  - Breyer J
AD  - Department of Urology, University of Regensburg, Regensburg, Germany.
FAU - Otto, Wolfgang
AU  - Otto W
AD  - Department of Urology, University of Regensburg, Regensburg, Germany.
FAU - Keck, Bastian
AU  - Keck B
AD  - Department of Urology and Pediatric Urology, Friedrich-Alexander University (FAU) 
      Erlangen-Nurnberg, Erlangen, Germany.
FAU - Hartmann, Arndt
AU  - Hartmann A
AD  - Institute of Pathology, Friedrich-Alexander University (FAU) Erlangen-Nurnberg, 
      Erlangen, Germany.
FAU - Bolenz, Christian
AU  - Bolenz C
AD  - Department of Urology and Pediatric Urology, University of Ulm, Ulm, Germany.
CN  - BRIDGE Consortium e.V.
LA  - eng
GR  - 110541/Deutsche Krebshilfe/
PT  - Journal Article
DEP - 20181127
PL  - Germany
TA  - Virchows Arch
JT  - Virchows Archiv : an international journal of pathology
JID - 9423843
RN  - 0 (Estrogen Receptor alpha)
RN  - 0 (Gonadal Steroid Hormones)
RN  - 0 (RNA, Messenger)
RN  - 0 (Receptors, Androgen)
RN  - 0 (Receptors, Progesterone)
RN  - 0 (Receptors, Steroid)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Estrogen Receptor alpha/genetics
MH  - Female
MH  - Gonadal Steroid Hormones
MH  - Humans
MH  - Kaplan-Meier Estimate
MH  - Lymphatic Metastasis
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Recurrence, Local
MH  - Prognosis
MH  - RNA, Messenger/genetics
MH  - Receptors, Androgen/genetics
MH  - Receptors, Progesterone/genetics
MH  - Receptors, Steroid/*genetics
MH  - Transcriptome/genetics
MH  - Urinary Bladder/metabolism
MH  - Urinary Bladder Neoplasms/*genetics
MH  - Urologic Neoplasms
OTO - NOTNLM
OT  - Androgen receptor
OT  - Bladder cancer
OT  - ESR
OT  - Estrogen receptor
OT  - Progesterone receptor
OT  - Urothelial carcinoma
FIR - Erben, Philipp
IR  - Erben P
FIR - Sikic, Danijel
IR  - Sikic D
FIR - Wirtz, Ralph M
IR  - Wirtz RM
FIR - Martini, Thomas
IR  - Martini T
FIR - Breyer, Johannes
IR  - Breyer J
FIR - Otto, Wolfgang
IR  - Otto W
FIR - Keck, Bastian
IR  - Keck B
FIR - Hartmann, Arndt
IR  - Hartmann A
FIR - Bolenz, Christian
IR  - Bolenz C
EDAT- 2018/11/30 06:00
MHDA- 2019/03/21 06:00
CRDT- 2018/11/29 06:00
PHST- 2018/01/08 00:00 [received]
PHST- 2018/11/19 00:00 [accepted]
PHST- 2018/10/10 00:00 [revised]
PHST- 2018/11/30 06:00 [pubmed]
PHST- 2019/03/21 06:00 [medline]
PHST- 2018/11/29 06:00 [entrez]
AID - 10.1007/s00428-018-2496-9 [pii]
AID - 10.1007/s00428-018-2496-9 [doi]
PST - ppublish
SO  - Virchows Arch. 2019 Feb;474(2):209-217. doi: 10.1007/s00428-018-2496-9. Epub 2018 
      Nov 27.